Market Intelligence, Clinical Progress, and High-Purity Reagents for Non-Small Cell Lung Cancer (NSCLC) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EGFR Exon20ins drug discovery. Below is a consolidated list of components, covering both kinase domain antigens, extracellular domain (ECD) reagents, gene delivery tools, and validated controls.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Kinase Domain) | EGFR Exon20ins Mutant Kinase Domain (A763_Y764insFQEA, S768_D770insSVD, D770insNPG). High purity (>95%), Sequence Verified, ATP-binding site accessible. | View EGFR Exon20ins Products |
| Antigen (ECD) | EGFR Exon20ins ECD-Fc Fusion. HEK293 expressed, native glycosylation, conformational epitope preservation. | View EGFR Exon20ins Products |
| Gene Delivery | EGFR Exon20ins Lentivirus Premade Particles. Full-length mutant ORF for stable Ba/F3 or NSCLC cell line construction. | View EGFR Exon20ins Products |
| Benchmark Ab | Anti-EGFR Amivantamab Biosimilar (EGFR/c-Met bispecific). Recombinant positive control, dual specificity reference. | View EGFR Exon20ins Products |
| Validator | EGFR siRNA Set. For knockdown verification and specificity controls. | View EGFR Products |
| Related Target: MET | Co-target for bispecific strategies (e.g., Amivantamab mechanism) and resistance bypass. | View MET Products |
| Related Target: HER2 | Parallel Exon20 insertion biology (Y772_A775dup), structural homology for selectivity assays. | View HER2 Products |
| Related Target: HER3 | Emerging target for dual-targeting ADCs in EGFR-mutant refractory settings. | View HER3 Products |
| Related Target: EGFR (WT) | Wild-type control for selectivity profiling and safety assessment. | View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant Selectivity vs WT EGFR | Purified Exon20ins Kinase Domain with sequence-verified mutation; high purity (>95%) minimizes WT contamination risks. |
| Multiple Insertion Variants Coverage | Panel of distinct Exon20ins mutations available (A763_Y764insFQEA, S768_D770insSVD, D770_N771insG, etc.), Sequence Verified. |
| Cross-species Cyno/Mouse Evaluation | Human/Cyno/Mouse ortholog protein pairs available with Endotoxin <1 EU/µg. |
| Bispecific Cross-linking Validation | MET ECD-Fc co-available for hetero-dimerization assays; theoretical MW verified. |
| Internalization Efficiency (ADC) | High-purity ECD-Fc for FACS-based internalization quantification; HEK293 expressed for native glycosylation patterns. |
| Cell-Based Conformation Screening | High-titer Lentivirus for establishing stable Ba/F3 or HEK293 cell lines. |
| Lack of Positive Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included. |
| False Positives in Knockdown Assays | Validated siRNA included for specificity checks. |
Live EGFR Exon20ins R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EGFR Exon20ins therapeutics is intensifying, with major players shifting focus from traditional ATP-competitive TKIs to bispecific antibodies, allosteric inhibitors, and ADCs. Following the approval of Amivantamab (EGFR/MET bispecific) and the withdrawal of Mobocertinib due to toxicity concerns, the field is prioritizing selectivity-driven modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting acquired resistance mutations (e.g., MET amplification, C797S) and combination strategies with chemotherapy or immunotherapy. Additionally, subcutaneous (Sub-Q) formulations are being developed to improve patient convenience and reduce infusion reactions, representing a key competitive differentiator for large molecules.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibody | Janssen (Amivantamab), Elpiscience | NSCLC (1L/2L) | Dual binding validation (EGFR+MET), internalization assay (need high-purity ECD-Fc). |
| ADC | Bluenessy Med, ZhenGe Biologics, Baili-Bio (BL-B01D1) | Solid Tumors, Refractory | Mutant-selective internalization, endotoxin-controlled (<1 EU/µg) payload conjugation. |
| Allosteric Inhibitor | Blueprint Medicines, AbbVie | Refractory NSCLC | Mutant vs WT Kinase Domain selectivity assay (need conformation-specific mutant proteins). |
| PROTAC | C4 Therapeutics, Biogen | Resistant Mutations | Binary/ternary complex formation (need pure KD + E3 ligase). |
| Specialized TKI | Dizal Pharma (Sunvozertinib), Allist, Cullinan (Zipalertinib) | Advanced NSCLC | Selectivity assay (need precisely validated WT vs Exon20ins Kinase Domains). |
Target Identity Note
Note: The requested target "EGFR Exon20ins" refers to a specific class of insertion mutations in exon 20 of the EGFR gene. It is distinct from wild-type EGFR or other common mutations (e.g., L858R, T790M, EGFRvIII). All reagents and assays are designed to address the unique structural and functional challenges posed by Exon20 insertions, including their proximity to the C-helix and the constricted ATP-binding pocket.